 |
|
Arthritis drug might prove effective in fighting the flu, study suggests
May 27, 2009University of Maryland researchers see potential new treatment approach in targeting immune response to virus
Researchers at the University of Maryland School of Medicine have found that an approved drug for treating rheumatoid arthritis reduces severe illness and death in mice exposed to the Influenza A virus. Their findings suggest that tempering the response of the body's immune system to influenza infection may alleviate some of the more severe symptoms and even reduce mortality from this virus.
The scientists report in the June 1 edition of The Journal of Immunology, which is now available online, that mice infected with the Influenza A virus responded favorably to a drug called Abatacept, which is commonly used to treat people with rheumatoid arthritis. The mice had been given "memory" T-cells, or white blood cells that have been primed to fight the invading virus as the result of previous exposure to Influenza A.
"We found that treating the mice with Abatacept minimized tissue damage caused by the immune response, but still enabled the body to rid itself of the virus. The mice didn't become as sick, recovered much faster and had much less damage to the lungs, compared to mice that weren't given the drug," says Donna L. Farber, Ph.D., a professor of surgery and microbiology and immunology at the University of Maryland School of Medicine and the study's senior author.
"Moreover, treatment with Abatacept significantly improved survival for mice infected with a lethal dose of influenza virus," Dr. Farber says. "The survival rate for the treated mice was 80 percent, compared to 50 percent for the mice that weren't treated."
She explains that the drug does not interrupt the immune system's early, rapid attack in the lungs, which helps to kill the virus, but it prevents "memory" T-cells from overreacting, which produces multiple negative effects. "It's this overactive immune response that can make you feel sick - and can also lead to pneumonia," she says.
The study's lead author, John R. Teijaro, a researcher in Dr. Farber's lab, notes that tissue damage caused by this vigorous immune response - often most prevalent in young, healthy people - is thought to be the leading cause of death from pandemic strains of flu, such as the avian flu and the 1918 Spanish flu. It is also thought to be true of the early cases of H1N1 "swine" flu.
Dr. Farber says, "We believe that our findings are very significant because they provide a potential new treatment for infection by the influenza virus - one that would dampen the immune response, yet still preserve its protective effects."
The researchers are now testing Abatacept in mice that have not previously been exposed to the flu virus, trying to determine how well they respond to the drug once they have become very sick. Instead of having "memory" T-cells, these mice have what are known as "naïve" T-cells, which have never been activated by being exposed to influenza previously. Depending on the results, Dr. Farber hopes to one day bring this promising new immunotherapy to the clinic for the benefit of patients.
E. Albert Reece, M.D., Ph.D., M.B.A., vice president for medical affairs, University of Maryland, and dean of the University of Maryland School of Medicine, says, "The results of this study are very promising. Influenza is a significant public health problem, affecting millions around the world each year. We hope that this study - and Dr. Farber's continuing research - will pave the way for identifying an effective treatment," Dr. Reece says.
Abatacept, which is manufactured by Bristol-Myers Squibb and marketed under the name Orencia, is already approved by the U.S. Food and Drug Administration for treatment of rheumatoid arthritis. The drug is not approved for treating influenza.
The study, funded by the National Institutes of Health and Bristol-Myers Squibb, is available online at http://www.jimmunol.org/cgi/content/full/182/11/6834. The Journal of Immunology is a peer-reviewed publication of the American Association of Immunologists.
There are three types of seasonal influenza, A, B and C, and a number of subtypes of Influenza A, including a new strain of the H1N1 virus, also known as the "swine flu," which has recently emerged and caused illness and a number of deaths this year in Mexico, the United States and other countries around the world.
Vaccination is the most effective way to prevent someone from getting the flu or having a serious case of the disease. An antiviral drug, Tamiflu, can help to prevent the flu virus from spreading within the body if it is taken within 48 hours of the first symptoms.
Dr. Farber points out that an immunotherapy with a drug such as Abatacept would be effective against different strains of the virus because the target of the drug would be the immune system, not the virus itself. "We're very excited about the potential of developing a new therapy, which possibly could be given to people even after they are very sick," she says.
University of Maryland Medical Center
"We found that treating the mice with Abatacept minimized tissue damage caused by the immune response, but still enabled the body to rid itself of the virus. The mice didn't become as sick, recovered much faster and had much less damage to the lungs, compared to mice that weren't given the drug," says Donna L. Farber, Ph.D., a professor of surgery and microbiology and immunology at the University of Maryland School of Medicine and the study's senior author.
"Moreover, treatment with Abatacept significantly improved survival for mice infected with a lethal dose of influenza virus," Dr. Farber says. "The survival rate for the treated mice was 80 percent, compared to 50 percent for the mice that weren't treated."
She explains that the drug does not interrupt the immune system's early, rapid attack in the lungs, which helps to kill the virus, but it prevents "memory" T-cells from overreacting, which produces multiple negative effects. "It's this overactive immune response that can make you feel sick - and can also lead to pneumonia," she says.
The study's lead author, John R. Teijaro, a researcher in Dr. Farber's lab, notes that tissue damage caused by this vigorous immune response - often most prevalent in young, healthy people - is thought to be the leading cause of death from pandemic strains of flu, such as the avian flu and the 1918 Spanish flu. It is also thought to be true of the early cases of H1N1 "swine" flu.
Dr. Farber says, "We believe that our findings are very significant because they provide a potential new treatment for infection by the influenza virus - one that would dampen the immune response, yet still preserve its protective effects."
The researchers are now testing Abatacept in mice that have not previously been exposed to the flu virus, trying to determine how well they respond to the drug once they have become very sick. Instead of having "memory" T-cells, these mice have what are known as "naïve" T-cells, which have never been activated by being exposed to influenza previously. Depending on the results, Dr. Farber hopes to one day bring this promising new immunotherapy to the clinic for the benefit of patients.
E. Albert Reece, M.D., Ph.D., M.B.A., vice president for medical affairs, University of Maryland, and dean of the University of Maryland School of Medicine, says, "The results of this study are very promising. Influenza is a significant public health problem, affecting millions around the world each year. We hope that this study - and Dr. Farber's continuing research - will pave the way for identifying an effective treatment," Dr. Reece says.
Abatacept, which is manufactured by Bristol-Myers Squibb and marketed under the name Orencia, is already approved by the U.S. Food and Drug Administration for treatment of rheumatoid arthritis. The drug is not approved for treating influenza.
The study, funded by the National Institutes of Health and Bristol-Myers Squibb, is available online at http://www.jimmunol.org/cgi/content/full/182/11/6834. The Journal of Immunology is a peer-reviewed publication of the American Association of Immunologists.
There are three types of seasonal influenza, A, B and C, and a number of subtypes of Influenza A, including a new strain of the H1N1 virus, also known as the "swine flu," which has recently emerged and caused illness and a number of deaths this year in Mexico, the United States and other countries around the world.
Vaccination is the most effective way to prevent someone from getting the flu or having a serious case of the disease. An antiviral drug, Tamiflu, can help to prevent the flu virus from spreading within the body if it is taken within 48 hours of the first symptoms.
Dr. Farber points out that an immunotherapy with a drug such as Abatacept would be effective against different strains of the virus because the target of the drug would be the immune system, not the virus itself. "We're very excited about the potential of developing a new therapy, which possibly could be given to people even after they are very sick," she says.
University of Maryland Medical Center
Influenza Current Events and Influenza News RSSU.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat
Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.
Poll: Many parents, high-priority adults who tried to get H1N1 vaccine unable to get it
A new national poll from Harvard School of Public Health (HSPH) researchers found that a majority of adults who tried to get the H1N1 vaccine for themselves or their children have been unable to do so.
When should flu trigger a school shutdown?
As flu season approaches, parents around the country are starting to face school closures. But how bad should an influenza outbreak be for a school to shut down?
Common Pain Relievers May Dilute Power of Flu Shots
With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system.
There's a speed limit to the pace of evolution, Penn biologists say
Researchers at the University of Pennsylvania have developed a theoretical model that informs the understanding of evolution and determines how quickly an organism will evolve using a catalogue of "evolutionary speed limits."
Initial Results Show Pregnant Women Mount Strong Immune Response To One Dose of 2009 H1N1 Flu Vaccine
Healthy pregnant women mount a robust immune response following just one dose of 2009 H1N1 influenza vaccine, according to initial results from an ongoing clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.
Flu vaccine given to women during pregnancy keeps infants out of the hospital
Infants born to women who received influenza vaccine during pregnancy were hospitalized at a lower rate than infants born to unvaccinated mothers.
Pandemic flu vaccine campaigns may be undermined by coincidental medical events
The effectiveness of pandemic flu vaccination campaigns - like that now underway for H1N1 - could be undermined by the public incorrectly associating coincidental and unrelated health events with the vaccines.
Scientists discover influenza's Achilles heel: Antioxidants
As the nation copes with a shortage of vaccines for H1N1 influenza, a team of Alabama researchers have raised hopes that they have found an Achilles' heel for all strains of the flu-antioxidants.
NIAID scientists propose new explanation for flu virus antigenic drift
Influenza viruses evade infection-fighting antibodies by constantly changing the shape of their major surface protein.
More Influenza Current Events and Influenza News Articles
 |
The Great Influenza: The story of the deadliest pandemic in history by John M. Barry (Author) At the height of WWI, history’s most lethal influenza virus erupted in an army camp in Kansas, moved east with American troops, then exploded, killing as many as 100 million people worldwide. It killed more people in twenty-four months than AIDS killed in twenty-four years, more in a year than the Black Death killed in a century. But this was not the Middle Ages, and 1918 marked the first collision of science and epidemic disease. Magisterial in its breadth of perspective and depth of research and now revised to reflect the growing danger of the avian flu, The Great Influenza is ultimately a tale of triumph amid tragedy, which provides us with a precise and sobering model as we confront the epidemics looming on our own horizon. John M. Barry has written a new ... |
 |
A Cruel Wind: Pandemic Flu in America 1918-1920 by Dorothy A. Pettit (Author) The flu pandemic that began in 1918 touched with illness virtually every family in America. It was a devastating time, far overshadowing the carnage of World War I as the pandemic killed more people in less time than any disease before or since. With 25% to 30% of the worlds population having clinically apparent illnesses and a mortality rate of 2.5% - 5%, it is believed that more than 675,000 Americans were among the 50-100 million that died worldwide. Because many experts believe that it is not a matter of if the world will encounter another 1918-like flu pandemic, but when, this social history of the pandemic should be considered essential reading for students, public health officials, doctors, nurses, journalists, and those in government office, interested in learning what workedand... |
 |
Flu : The Story Of The Great Influenza Pandemic by Gina Kolata (Author) A scientific history of the Great Flu Epidemic of 1918, which killed at least 40 million people. The author details the science and latest understanding of flu, examines the chances of a great epidemic recurring and explores what can be done to prevent it. |
 |
Flu: A Social History of Influenza by Tom Quinn (Author) It may sound innocuous compared to war, plague and famine, but flu is in fact one of the world's biggest killers. Strains of the virus are always in circulation but every so often a new and particularly virulent one comes along, to which we have no historic immunity - when that happens the consequences are devastating. This fascinating book explores the havoc caused by the world's most deadly virus - and the destruction left in its wake. From its initial identification by the Greek physician Hippocrates in the 4th century BC to the Spanish flu pandemic of 1918 and beyond, Tom Quinn explores the social, medical and scientific ramifications of the major outbreaks that have occurred over the centuries - and the potential consequences should such a pandemic occur in the modern world, an event... |
 |
American Experience - Influenza 1918 Starring: David McCullough, David Ogden Stiers, Joe Morton, Linda Hunt, Will Lyman Also With: Katy Mostoller (Producer), Michael Rossi (Producer), Rocky Collins (Producer), Rocky Collins (Writer), Tracy Heather Strain (Producer), Henry Hampton (Writer) As the nation mobilized for war in the spring of 1918, ailing Private Albert Gitchell reported to an army hospital in Kansas. He was diagnosed with the flu, a disease about which doctors knew little. Before the year was out, America would be ravaged by a flu epidemic that killed 675,000 people--more than died in all the wars of this century combined--before disappearing as mysteriously as it began. |
 |
The Devil's Flu: The World's Deadliest Influenza Epidemic and the Scientific Hunt for the Virus That Caused It by Pete Davies (Author) A gripping account of the 1918 flu pandemic and the modern-day hunt for this elusive and deadly virus In 1918, a flu virus more lethal than any that has come along since swept through the world, from the remotest villages in Arctic climates to crowded U.S.cities to the battlefields of Europe, killing forty million people. Yet, despite its devastating toll and the probability that other deadly pandemics await on the horizon, it was relegated to a footnote in history. The Devil's Flu is the extraordinary story of 1918's forgotten tragedy and of the global scientific community's effort to avert another such disaster. The 1918 flu still so intrigues and frightens experts in the field that in 1998, a group of respected scientists journeyed to the Norwegian Arctic Circle in search... |
 |
Influenza Virology: Current Topics by Yoshihiro Kawaoka (Author) |
 |
America's Forgotten Pandemic: The Influenza of 1918 by Alfred W. Crosby (Author) Between August 1918 and March 1919 the Spanish influenza spread worldwide, claiming over 25 million lives, more people than those perished in the fighting of the First World War. It proved fatal to at least a half-million Americans. Yet, the Spanish flu pandemic is largely forgotten today. In this vivid narrative, Alfred W. Crosby recounts the course of the pandemic during the panic-stricken months of 1918 and 1919, measures its impact on American society, and probes the curious loss of national memory of this cataclysmic event. In a new edition, with a new preface discussing the recent outbreaks of diseases, including the Asian flu and the SARS epidemic, America's Forgotten Pandemic remains both prescient and relevant. Alfred W. Crosby is a Professor Emeritus in American Studies,... |
 |
Rapid Reference to Influenza by Jan Wilschut (Author), Janet Mcelhaney (Author), Abraham Palache (Author) Provides the reader with authoritative and accessible information on the subject of influenza. Clearly written by key experts in the field and highly illustrated in full colour, the book provides an overview of influenza, its pathogenesis, epidemiology, the burden of disease and its health economics. Rapid Reference Influenza also summarises available information on the molecular biology of influenza and the emergence of new influenza viruses. Completely updated with the latest information on H5N1, the book aims to contribute to international efforts to emphasize the major burden of influenza and the need for better control. * Expert information succinctly written for ease of use. * Abundant use of bulleted lists and short tables, for quick access to comparative information. * Presents... |
 |
H1N1 and Swine Influenza (Flu) Protection Kit w/ N95 Masks - Meets CDC Guidelines for H1N1 and Swine Flu by JIB EDP Protect against all Influenza's (Flu) Help protect yourself and your family with this Flu Defense Kit. The masks contained in the kit are N95 rated and meet guidelines set forth by the CDC and the Department of Health and Human Services for influenza (flu) protection. In addition to this kit, you MUST: Stay informed. - Influenza is thought to spread mainly person-to-person through coughing or sneezing of infected people. - Take everyday actions to stay healthy. -Cover your nose and mouth with a tissue when you cough or sneeze. Throw the tissue in the trash after you use it. - Wash your hands often with soap and water, especially after you cough or sneeze. Alcohol-based hands cleaners are also effective. - Avoid touching your eyes, nose or mouth. Germs spread that way. - Stay home... |
| © 2009 BrightSurf.com |